GLP-1/Weight Loss

Laprophan's acquisition of Rivopharm is more than a deal; it's a strategic blueprint for emerging market players aiming for the global pharmaceutical stage.

As giants rule the obesity market, small-cap MetaVia pitches a novel dual-agonist and a first-in-class MASH drug. Can its science win the day?

With 33% growth dwarfing industry norms, NNB Nutrition's integrated model and fermentation tech aren't just winning—they're rewriting the rules for wellness.

A new Illinois wellness center combines FDA-cleared depression therapy with cosmetic treatments, raising critical questions about the future of healthcare delivery.

Medincell's latest results show a planned loss but reveal a strategic shift to recurring royalties, fueled by UZEDY®'s success and a pipeline set for growth.

With a novel non-hallucinogenic drug, Enveric Biosciences heads to the BIO convention seeking partners. Can its unique science secure its future?

Quoin Pharma's new data for a rare skin disease shows life-changing results in children, offering hope for families. What do the numbers really mean?

BioAge Labs starts a Phase 2 trial for BGE-102, an oral drug targeting inflammation to reduce heart risk, a strategy that could redefine cardiovascular care.

Eli Lilly's Zepbound secures a landmark approval for sleep apnea, moving beyond weight loss to redefine chronic disease management and challenge competitors.

New clinical trial results for XWRAP® show a significant leap in healing diabetic ulcers, positioning Applied Biologics as a formidable player in a challenging field.

The journey from brand launch to retail shelf has shrunk from years to just 18 months. A new playbook reveals how TikTok data and GLP-1 drugs are the forces behind this massive shift.

A 23% national drop in overdose deaths signals progress, but regional disparities and a volatile drug supply show the fight is far from over.

Lexeo Therapeutics finalizes a pivotal trial for its Friedreich ataxia gene therapy, leveraging a novel trial design and accelerated FDA pathway.

Aussie biotech ENA Respiratory secures crucial US patents for its novel immune modulator, signaling a major strategic move in the multi-billion dollar fight against COPD.

A breakthrough publication identifies a novel protein, LanCL1, as a key target for neuropathic pain, validating a new class of drugs for millions of sufferers.

Kymera Therapeutics reports promising data for KT-621, a first-in-class oral drug that removes a key inflammatory protein, not just block it.

MBX Biosciences' new one-year data for canvuparatide isn't just a clinical win; it's a calculated move to dominate a billion-dollar market left vacant.

With a new CMO, Get A Drip is capitalizing on the longevity trend. But as it expands, it faces questions on scientific rigor and regulatory oversight.

A new FDA-designated device aims to filter a deadly protein from the blood of sepsis patients. Can this novel approach finally conquer a global health crisis?

With over 55,000 on waitlists for the UK's first oral weight-loss pill, the market is set to explode. But strict rules and high hopes face a reality check.